GlobeNewsWire
03 Aug 2026, 11:40 UTC · 13w ago
Impact · against what's priced in
The appointment of Michael Halstead is a positive catalyst for HELP, as he brings specific, proven experience in scaling a CNS company and executing a multi-billion dollar exit to J&J. Additionally, the confirmation of completed enrollment for the APPROACH study reduces execution risk ahead of the Q4 2026 data readout.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Helus Pharma expects topline data from its first pivotal Phase 3 study (APPROACH) for HLP003 in the treatment of Major Depressive Disorder in Q4 2026.
So whatTopline Phase 3 results are the primary binary catalyst for clinical-stage biotech valuations.
More positive than 93% of claims this week
Helus Pharma appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO.
So whatHalstead has a proven track record of scaling a similar CNS company and overseeing a $14.6 billion exit to Johnson & Johnson.
Continue reading
5 related stories
The hire of a CEO who previously led Intra-Cellular Therapies through a $14.6 billion sale to J&J provides high-level operational expertise for HLP003's commercialization. Completed enrollment in the APPROACH study further secures the timeline for Q4 2026 topline results.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 76% of claims this week
Enrollment is complete for the APPROACH study, while enrollment continues for the second pivotal Phase 3 study, EMBRACE.
So whatCompletion of enrollment reduces execution risk and confirms the timeline for the Q4 data readout.
More positive than 48% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
+14.6%
Price agrees with the score
$8.96 vs $7.82 close before publication (Jul 31) · not market-adjusted
HELP chart →
